Chemical Component Summary

NamePrinomastat
Synonyms(3S)-N-hydroxy-2,2-dimethyl-4-{[4-(pyridin-4-yloxy)phenyl]sulfonyl}thiomorpholine-3-carboxamide
Identifiers(3S)-N-hydroxy-2,2-dimethyl-4-(4-pyridin-4-yloxyphenyl)sulfonyl-thiomorpholine-3-carboxamide
FormulaC18 H21 N3 O5 S2
Molecular Weight423.506
TypeNON-POLYMER
Isomeric SMILESCC1([C@@H](N(CCS1)S(=O)(=O)c2ccc(cc2)Oc3ccncc3)C(=O)NO)C
InChIInChI=1S/C18H21N3O5S2/c1-18(2)16(17(22)20-23)21(11-12-27-18)28(24,25)15-5-3-13(4-6-15)26-14-7-9-19-10-8-14/h3-10,16,23H,11-12H2,1-2H3,(H,20,22)/t16-/m0/s1
InChIKeyYKPYIPVDTNNYCN-INIZCTEOSA-N

Chemical Details

Formal Charge0
Atom Count49
Chiral Atom Count1
Bond Count51
Aromatic Bond Count12

Drug Info: DrugBank

DrugBank IDDB05100 
NamePrinomastat
Groups investigational
DescriptionPrinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier.
Synonyms
  • Prinomastatum
  • Prinomastat
IndicationInvestigated for use/treatment in brain cancer, lung cancer, and prostate cancer.
Categories
  • Enzyme Inhibitors
  • Matrix Metalloproteinase Inhibitors
  • Protease Inhibitors
CAS number192329-42-3

Related Resource References

Resource NameReference
Pharos CHEMBL75094
PubChem 466151
ChEMBL CHEMBL75094
ChEBI CHEBI:138885